Dysregulation of MYCN is observed in various tumors in both pediatric and adult settings, encompassing neuroblastoma, Wilms’ tumor, rhabdomyosarcoma, lung cancer, medulloblastoma, retinoblastoma and basal cell carcinoma (5–8, 36–41). Here, MYCN is linked to rhabdomyosarcoma.